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Redox Biology
To the Editor I read with interest the article by Cortese-Krott and Kelm [1] who reviewed and discussed the at first glance paradoxical, yet potentially important and formidably challenging issue of nitric oxide (NO) synthesis from L-arginine by endothelial NO synthase (eNOS) in red blood cells (RBCs), a possibly new erythrocrine function. In consideration of the high concentration of hemoglobin in erythrocytes (about 10 mM) and the high affinity of O 2 , NO and carbon monoxide (CO) and presumably of other gases to the heme group of hemoglobin, the majority of scientists believes that RBCs behave toward NO as do super-massive black holes behave against matter and even light, with other words as "NO sinks". Yet, in practice we see that RBCs are able to export NO and other NO species that can finally exert cGMPdependent and cGMP-independent NO-related activities in the circulation. With respect to this issue I fully agree with the statements, arguments and conclusions by Cortese-Krott and Kelm in their review article [1] . However, I do not agree with the authors on their argument concerning the alleged chemistry of NOS-derived NO in RBCs and that this particular NO chemistry may explain our failure to measure NOS activity in human RBCs by means of a previously reported, fullyvalidated [2] and cross-validated [3] gas chromatography-mass spectrometry (GC-MS) NOS activity assay.
The principle of our GC-MS NOS activity assay [2] used in vivo and in vitro in blood cells including human RBCs [4] and platelets [3, 5] and the major reactions of NO and its major metabolites/reaction products, nitrate and nitrite, are illustrated in Fig. 1 In this context, we should also not disregard the several orders of magnitude molar excess of hemoglobin over diaminofluorescein (DAF) reagents. With respect to our fully-validated GC-MS NOS activity assay [2] , which is both specific and sensitive and works equally well in numerous complex biological matrixes, including plasma, serum, whole blood, erythrocytes, saliva, urine, tissues (liver, kidney, stomach, lung, brain), and various cells [2] [3] [4] [5] [6] [9] [10] [11] , the failure to measure NOS activity in RBCs [4] and platelets [5] of healthy subjects under regular experimental conditions is not an analytical issue. With regard both to human RBCs and human platelets, our studies indicate that these cell types lack NOS activity.
As to human blood platelets, there is convincing evidence by a proteomics-based study that these cells do not express any NOS proteins [12] . Detection of NOS proteins in human blood platelets by many other groups are likely to be due to the use of unspecific NOS antibodies [13] . It is generally accepted for many years that (human) blood platelets express functional NOS. However, not only recently reported studies but also studies reported 25 years ago, for instance by the group of Vane [14] , suggest that human platelets lack NOS activity and that measurement of NOS activity in platelets preparations are likely to be artefactual due to contaminating neutrophils and mononuclear cells [14] .
Kelm and his scientific partners are long-standing leaders in the area of NO research and have contributed significant work including the development of sophisticated analytical methods and clinical protocols to study the pathophysiology of NO in the human vasculature. Kelm and colleagues reported both on the expression and the functionality of eNOS in RBCs of healthy and sick subjects [15, 16] . As our group did not investigate the occurrence of NOS proteins in human RBCs, we cannot comment on the presence or absence of NOS proteins in human RBCs (and human blood platelets). Yet, the discrepancy concerning the functionality of NOS in human RBCs between our groups remains unresolved at present. Even if NOS would be present and active in RBCs, its activity would be very low. I am convinced that the most reliable way to assess NOS activity is the use of [17] [18] [19] . Measurement of unlabeled, stable-isotope labeled [3] and/or radiolabeled citrulline produced from the respective L-arginine species by enzymes-involving pathways distinctly different from L-arginine/NOS also bears the risk of detecting artefactually NOS activity. Specific detection of NOS proteins and unequivocal measurement of their activity in blood cells are big analytical challenges. Our knowledge about NO chemistry, biochemistry and pathophysiology grew enormously in the past decades. The unimaginable complexity of the cellular biology bears a high risk of generating inaccurate analytical results and of drawing uncertain conclusions. By nature, RBCs represent an especially difficult terrain to NO researchers interested in expression and functionality of erythrocytic NOS, like the black holes to astronomers. The enigma and the paradox of expression and Fig. 1 . Schematic of the GC-MS-based NOS activity assay [2] adopted for the measurement of NOS activity in RBCs [4] . functionality of NOS in RBCs remain to be elucidated. Mass spectrometry is the key analytical tool in this endeavor.
